Blue is good for Bluebird as it snags "blue chip" $60m
This article was originally published in Scrip
Bluebird Bio raised $60 million in Series D financing to advance its novel approach to gene therapy for severe genetic disorders, which involves the insertion of healthy versions of disease-causing genes into stem cells harvested from a patient's bone marrow.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.